EBV latent membrane protein 1 activates Akt, NFkappaB, and Stat3 in B cell lymphomas.

EBV latent membrane protein 1 activates Akt, NFkappaB, and Stat3 in B cell lymphomas.

Latent membrane protein 1 (LMP1) is the major oncoprotein of Epstein-Barr virus (EBV). In transgenic mice, LMP1 promotes increased lymphoma development by 12 mo of age. This study reveals that lymphoma develops in B-1a lymphocytes, a population that is associated with transformation in older mice. T...

Full description

Bibliographic Details
Main Authors:	Kathy H Y Shair, Katherine M Bendt, Rachel H Edwards, Elisabeth C Bedford, Judith N Nielsen, Nancy Raab-Traub
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2007-11-01
Series:	PLoS Pathogens
Online Access:	http://europepmc.org/articles/PMC2065877?pdf=render

Similar Items

CFTR is a negative regulator of NFkappaB mediated innate immune response.
by: Neeraj Vij, et al.
Published: (2009-01-01)

Allele-specific regulation of matrix metalloproteinase-3 gene by transcription factor NFkappaB.
by: Veronika Souslova, et al.
Published: (2010-03-01)

Siglecg limits the size of B1a B cell lineage by down-regulating NFkappaB activation.
by: Cheng Ding, et al.
Published: (2007-01-01)

Vascular endothelial growth factor signalling in endothelial cell survival: a role for NFkappaB.
by: Grosjean, J, et al.
Published: (2006)

TRAF6 autoubiquitination-independent activation of the NFkappaB and MAPK pathways in response to IL-1 and RANKL.
by: Matthew C Walsh, et al.
Published: (2008-01-01)

TWEAK activates the non-canonical NFkappaB pathway in murine renal tubular cells: modulation of CCL21.
by: Ana B Sanz, et al.
Published: (2010-01-01)

Role of NFkappaB in antigen presentation and development of regulatory T cells elucidated by treatment of dendritic cells with the proteasome inhibitor PSI.
by: Yoshimura, S, et al.
Published: (2001)

A genomewide survey of developmentally relevant genes in Ciona intestinalis. III. Genes for Fox, ETS, nuclear receptors and NFkappaB.
by: Yagi, K, et al.
Published: (2003)

Intracisternal delivery of NFkappaB-inducible scAAV2/9 reveals locoregional neuroinflammation induced by systemic kainic acid treatment.
by: Olivier eBockstael, et al.
Published: (2014-12-01)

Analysis of Porcine Transcriptional Response to <it>Salmonella enterica </it>serovar Choleraesuis suggests novel targets of NFkappaB are activated in the Mesenteric Lymph Node
by: Lunney Joan K, et al.
Published: (2008-09-01)

The expression of SOCS1 and TLR4-NFkappaB pathway molecules in neoplastic cells as potential biomarker for the aggressive tumor phenotype in laryngeal carcinoma.
by: Magdalena Bryś, et al.
Published: (2010-02-01)

Adenoviral transgene delivery provides an approach to identifying important molecular processes in inflammation: evidence for heterogenecity in the requirement for NFkappaB in tumour necrosis factor production.
by: Foxwell, B, et al.
Published: (2000)

Novel dinuclear platinum(II) complexes targets NFkappaB signaling pathway to induce apoptosis and inhibit metabolism of MCF-7 breast cancer cells.
by: Arkadiusz Surazyński, et al.
Published: (2010-01-01)

Rotavirus NSP1 inhibits NFkappaB activation by inducing proteasome-dependent degradation of beta-TrCP: a novel mechanism of IFN antagonism.
by: Joel W Graff, et al.
Published: (2009-01-01)

Adenoviral gene transfer into osteoarthritis synovial cells using the endogenous inhibitor IkappaBalpha reveals that most, but not all, inflammatory and destructive mediators are NFkappaB dependent.
by: Amos, N, et al.
Published: (2006)

Transcriptome Changes Induced by Epstein-Barr Virus LMP1 and LMP2A in Transgenic Lymphocytes and Lymphoma
by: Kathy H. Y. Shair, et al.
Published: (2012-11-01)

Targeting latent viral infection in EBV-associated lymphomas
by: Isabella Y. Kong, et al.
Published: (2024-02-01)

Silencing of PD-1 combined with EBV-specific killer T cells for the treatment of EBV-associated B lymphoma
by: Jiaping Wang, et al.
Published: (2024-02-01)

Hemin treatment drives viral reactivation and plasma cell differentiation of EBV latently infected B cells.
by: Anna M Burnet, et al.
Published: (2023-08-01)

Advances in the Pathogenesis of EBV-Associated Diffuse Large B Cell Lymphoma
by: Paola Chabay
Published: (2021-05-01)

Epstein-Barr Virus (EBV) Is Mostly Latent and Clonal in Angioimmunoblastic T Cell Lymphoma (AITL)
by: Racha Bahri, et al.
Published: (2022-06-01)

EBV & lymphoma
by: Dolores Caballero, (Coordinating Author)
Published: (2019-06-01)

Primary bilateral adrenal B-cell lymphoma associated with EBV and JCV infection
by: Guzzardo Vincenza, et al.
Published: (2009-01-01)

Updates on Epstein–Barr Virus (EBV)-Associated Nasopharyngeal Carcinoma: Emphasis on the Latent Gene Products of EBV
by: Naveed Ahmed, et al.
Published: (2022-12-01)

Resveratrol prevents EBV transformation and inhibits the outgrowth of EBV-immortalized human B cells.
by: J Luis Espinoza, et al.
Published: (2012-01-01)

Composite Lymphoma with Follicular Lymphoma Transformation to Clonally Related Epstein–Barr Virus (EBV) Positive Diffuse Large B-Cell Lymphoma and EBV-PositiveClassic Hodgkin Lymphoma
by: Christopher B. Ryder, et al.
Published: (2023-01-01)

EBV-Related Diffuse Large B-Cell Lymphoma in a Patient with Angioimmunoblastic T-Cell Lymphoma
by: Cem Şimşek, et al.
Published: (2019-02-01)

Glycoprotein B Antibodies Completely Neutralize EBV Infection of B Cells
by: Junping Hong, et al.
Published: (2022-05-01)

Lysine demethylase LSD1 is associated with stemness in EBV-positive B cell lymphoma
by: Joo Hyun Kim, et al.
Published: (2024-03-01)

B‐cell receptors of EBV‐negative Burkitt lymphoma bind modified isoforms of autoantigens
by: Theresa Bock, et al.
Published: (2022-08-01)

Advances in research on EBV positive diffuse large B-cell lymphoma, not otherwise specified
by: CHEN Guangliang, WU Fangtian, CAO Junning
Published: (2022-03-01)

EBV, HHV8 and HIV in B cell non Hodgkin lymphoma in Kampala, Uganda
by: Pileri Stefano A, et al.
Published: (2010-06-01)

EBV IN HODGKIN LYMPHOMA
by: Stefan Hohaus, et al.
Published: (2009-11-01)

Prognostic significance of EBV latent membrane protein 1 expression in lymphomas: evidence from 15 studies.
by: Yuan Mao, et al.
Published: (2013-01-01)

Spontaneous EBV-Reactivation during B Cell Differentiation as a Model for Polymorphic EBV-Driven Lymphoproliferation
by: Matthew A. Care, et al.
Published: (2023-06-01)

Epstein-Barr virus (EBV)-associated miRNAs are important for the maintenance of EBV transformed B cells
by: Luftig Micah, et al.
Published: (2010-10-01)

Epigenetic Impact on EBV Associated B-Cell Lymphomagenesis
by: Shatadru Ghosh Roy, et al.
Published: (2016-11-01)

Emergence of CD4+ and CD8+ Polyfunctional T Cell Responses Against Immunodominant Lytic and Latent EBV Antigens in Children With Primary EBV Infection
by: Janice K. P. Lam, et al.
Published: (2018-03-01)

Src kinase and Syk activation initiate PI3K signaling by a chimeric latent membrane protein 1 in Epstein-Barr virus (EBV)+ B cell lymphomas.
by: Olivia Hatton, et al.
Published: (2012-01-01)

Breast implant associated EBV-positive Diffuse Large B-cell lymphoma: an underrecognized entity?
by: Johanna Vets, et al.
Published: (2023-04-01)